Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

11 results about "Enterobacteriaceae bacterium" patented technology

Methods and kits for detecting the presence or absence and / or amount of enterobacteriaceae bacteria in a food or beverage sample, an environmental sample, or a biological sample

Provided is a method for detecting the presence or absence and / or amount of Enterobacteriaceae bacteria in a food or drink sample, an environmental sample, or a biological sample, in a short period of time, easily and efficiently. The method includes a step of simultaneously detecting the presence or absence and / or amount of at least two or more different genera of Enterobacteriaceae bacteria in a sample based on an antigen-antibody reaction.
Owner:ASAHI KASEI KOGYO KABUSHIKI KAISHA

A primer set for detecting important drug resistance and virulence genes in multidrug-resistant pathogens and its applications.

This invention relates to the field of high-throughput targeted sequencing technology, and particularly to a primer set and its applications for detecting important drug resistance and virulence genes in multidrug-resistant pathogens. Specifically, it includes primers for detecting various drug-resistant bacteria, such as third-generation cephalosporin-resistant Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, carbapenem-resistant Acinetobacter baumannii, and rifampicin-resistant Mycobacterium tuberculosis. This invention offers advantages such as speed, efficiency, strong targeting, and high specificity. It is suitable for analyzing the prevalence and differential distribution of multiple important drug resistance and virulence genes carried in metagenomic samples from various environments or pathogenic materials, and can be used to assess the risk of related environments, further guiding preventative and clinical treatment medications.
Owner:CHINA AGRI UNIV

Carbapenem drug resistance gene detection primer group based on multiple PCR-time-of-flight mass spectrometry, detection kit and kit use method

The invention discloses a carbapenem drug resistance gene detection primer group based on multiple PCR-time-of-flight mass spectrometry, a detection kit and a kit using method, and through a large number of screening and verification experiments, a multiple primer group suitable for time-of-flight mass spectrometry detection is obtained. Therefore, the multi-PCR-time-of-flight mass spectrometry detection of the multi-drug-resistant genes of carbapenem-resistant enterobacteriaceae bacteria becomes possible. The detection kit prepared by adopting the primer group can be used for simultaneously detecting and identifying 10 common carbapenem drug-resistant genes, including klebsiella pneumoniae KPC gene, NDM gene, IMP gene, VIM gene and OXA gene, acinetobacter baumannii OXA gene, NDM gene, Escherichia coli OXA gene, IMP gene and serratia marcescens VIM gene. Meanwhile, the kit is high in sensitivity and specificity, dozens of times of detection can be carried out in the same batch, so that the detection efficiency is greatly improved, and the kit is suitable for rapid screening and genetic typing of carbapenem drug-resistant bacteria in clinical samples.
Owner:LANZHOU BAIYUAN GENE TECH

Klebsiella pneumoniae H2208 strain and application thereof

The invention relates to the field of bioengineering, and discloses a klebsiella pneumoniae H2208 strain and application thereof. The preservation number of the strain is GDMCC No: 65187; the kit comprises a tool plasmid pMar, has two T4SS gene clusters, and has efficient autonomous transfer efficiency. The strain or plasmid has the following characteristics: reverse mobilization of large non-zygotic plasmids enables host bacteria to directly obtain the large non-zygotic plasmids; and directly mobilizing the large non-zygotic plasmids to join and transfer the large non-zygotic plasmids into the recipient bacteria. According to the application, the pMar plasmid is used as the helper plasmid, large virulence plasmids in H2208 and large non-zygotic plasmids with homologous oriT sequences in other enterobacteriaceae bacteria can be efficiently transferred to recipient bacteria, and an effective tool is provided for researching the evolution and evolution laws and virulence and drug resistance formation mechanisms of various pathogenic bacteria.
Owner:AFFILIATED HUSN HOSPITAL OF FUDAN UNIV

A method for preparing highly specific Salmonella pullorum plate agglutination antigen

The invention discloses a method for preparing a highly specific Salmonella pullorum plate agglutination antigen. The Salmonella pullorum C79-1 and C79-7 strains are revived and prepared into seed liquid, inoculated with a suitable culture medium, fermented and cultured according to a specific process, inactivated and centrifuged to collect the bacteria, and then washed at 121°C for 2 hours and multiple times to remove the protein antigen components that easily cross-react with Escherichia coli or other Enterobacteriaceae bacteria commonly found in the environment. The C79-1 and C79-7 strains are adjusted to a suitable bacterial concentration, Tween-20, crystal violet and glycerol are added, and the Salmonella pullorum plate agglutination antigen is obtained by sufficient homogenization. The antigen has higher specificity and is more accurate when used for pullorum purification detection. The bacterial yield according to the fermentation process is 4 times that of ordinary fermentation and 2 times that of solid culture. No ethanol precipitation is required, and the production cost is lower. Tween-20 is added to increase the surface tension of the antigen, solve the problem of difficulty in coating evenly during use, and provide a new and better diagnostic reagent for the purification of pullorum.
Owner:CHINA INST OF VETERINARY DRUG CONTROL

Method for producing infected animal model

PCT designated stageWO2026048935A1Animal husbandryESCHERICHIA COLI ANTIGENMacrolide resistance
The purpose of the present invention is to provide a method for producing an animal model infected with Enterobacteriaceae bacteria such as pathogenic Escherichia coli. Provided is a method for producing an animal model infected with Enterobacteriaceae bacteria, the method comprising step (1) and step (2) in the following order. (1) A step for administering a β-lactam antibacterial agent to a non-human mammal; (2) a step including the following steps (2-1) and (2-2) in random order; (2-1) a step for administering at least one selected from the group consisting of lincomycin antibacterial agents and macrolide antibacterial agents to the non-human mammal; and (2-2) a step for administering Enterobacteriaceae bacteria to the non-human mammal
Owner:CHIBA UNIV

Antibiotic-resistant bacteria

PendingUS20260183350A1Intestinal colonisationIntestino-intestinal
The present invention relates to antibiotic-resistant bacteria, and to the prevention or treatment of infections of drug-resistant pathogens, such as carbapenem-resistant Enterobacteriaceae (CRE) and / or vancomycin-resistant Enterococcus (VRE). In particular, the invention relates to the treatment or prevention of colonisation of CRE and / or VRE in the gastrointestinal (GI) tract, before they cause invasive infections, for example in the blood. The invention provides novel formulations, pharmaceutical compositions and methods of using them to prevent or treat CRE and / or VRE infections or intestinal colonisations thereof.
Owner:IMPERIAL COLLEGE INNVOATIONS LTD

Antibacterial biphenyl compounds and uses thereof

Antibiotic resistance leads to deadly hospital-acquired infections globally. The World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) have identified priority bacteria, including Methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter baumannii, and particularly those carbapenem- resistant strains, also found in Enterobacterales (CRE) such as Escherichia coli and Klebsiella, as requiring new antibiotics. The present disclosure provides a chemical class of drugs less susceptible to existing mechanisms of antibiotic resistance and targeting difficult-to-treat bacterial infections. It more particularly provides compounds of formula (I), and compositions and uses thereof.
Owner:SCOPRA SCI & GENIE SEC

Chelating type composite micelle with antibacterial activity of Gram-negative bacteria and application of chelating type composite micelle

The invention discloses a chelating type composite micelle with Gram-negative bacterium antibacterial activity, which comprises metal ions, macromolecules with chelating blocks and an antibacterial agent with Lewis base functional groups, the antibacterial agent has the antibacterial activity of multiple drug-resistant Gram-negative bacteria (MDR-GNB), and the chelating type composite micelle has the antibacterial activity of multiple drug-resistant Gram-negative bacteria (MDR-GNB) and has the antibacterial activity of multiple drug-resistant Gram-negative bacteria (MDR-GNB) and the antibacterial activity of multiple drug-resistant Gram-negative bacteria (MDR-GNB). Such as carbapenem resistant Acinetobacter baumannii, Pseudomonas aeruginosa or Enterobacteriaceae bacteria.
Owner:ORIGINAL BIOMEDICALS

Antler dog chew toy

Packaged dog chew toy made from one or more pieces of antler, animal bone pieces or other animal by-products of Category 3, characterized by a partially sterilized state such that Salmonella or Enterobacteriaceae are killed.
Owner:WEIDNER GEORG